A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy. METHODS: In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo. RESULTS: Over a median of 58 weeks, interferon gamma-1b therapy did not significantly affect the primary end point of progression-free survival, defined as the time to disease progression or death, and no significant treatment effect was observed on measures of lung function, gas exchange, or the quality of life. Ten percent of patients in the interferon gamma-1b group died, as compared with 17 percent of patients in the placebo group (P=0.08). Treatment with interferon gamma-1b was associated with more frequent constitutional symptoms. However, the rates of treatment adherence and premature discontinuation of treatment were similar in the two groups. More pneumonias were reported among patients in the interferon gamma-1b group, but the incidence of severe or life-threatening respiratory tract infections was similar in the two groups. CONCLUSIONS: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Owing to the size and duration of the trial, a clinically significant survival benefit could not be ruled out.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, systemic administration of recombinant IFNγ (which would simulate the presence of Th1 biology) and monoclonal antibody-mediated neutralization of IL-13 (which would specifically target Th2 responses) failed to demonstrate efficacy in randomized, placebo-controlled trials of patients with IPF (141, 142).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [141]
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Nathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Self-citationinternational consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Gajewski, T. F., & Fitch, F. W. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.12.4245 · Cited by 834
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794
Research works printed but not linked: 1
- Okada T, 1993, Lymphokine Cytokine Res, 12, 87
Cited by
Items 101–200 of 649
Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function
Schmidt, S. L., Tayob, N., Han, M. K., Zappala, C. J., Kervitsky, D. J., Murray, S., Wells, A. U., Brown, K. K., Martínez, F. J., & Flaherty, K. R. (2013) · CHEST Journal · doi:10.1378/chest.13-0844 · Cited by 116
Self-citationAcute exacerbation of idiopathic pulmonary fibrosis: A systematic review
Agarwal, R., & Jindal, S. K. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.04.024 · Cited by 118
“Regarding the role of interferon-gamma 1b in causation of AE-IPF, a recent report that had analyzed 362 patients from two randomized, double-blind, placebo-controlled trials reported that the number of patients with serious respiratory adverse events throughout the study was similar in the interferon-gamma 1b and plac…”
BackgroundResultSwigris, J. J., Han, M. K., Vij, R., Noth, I., Eisenstein, E. L., Anstrom, K. J., Brown, K. K., & Fairclough, D. L. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2012.06.018 · Cited by 113
Self-citationIdiopathic pulmonary fibrosis: new insights into pathogenesis
Noble, P. W., & Homer, R. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.04.003 · Cited by 113
Self-citationAttenuation of Bleomycin-induced Pulmonary Fibrosis by Follistatin
Aoki, F., Kurabayashi, M., Hasegawa, Y., & Kojima, I. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200412-1620oc · Cited by 106
Raghu, G., Ghazipura, M., Fleming, T. R., Aronson, K. I., Behr, J., Brown, K. K., Flaherty, K. R., Kazerooni, E. A., Maher, T. M., Richeldi, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2213so · Cited by 92
Self-citationBlood Cell Count Derived Inflammation Indexes in Patients with Idiopathic Pulmonary Fibrosis
Zinellu, A., Paliogiannis, P., Sotgiu, E., Mellino, S., Mangoni, A. A., Zinellu, E., Negri, S., Collu, C., Pintus, G., Serra, A., et al. (2020) · Lung · doi:10.1007/s00408-020-00386-7 · Cited by 119
Lung infection with γ-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice
Mora, A. L., Woods, C. R., Garcia, A., Xu, J., Rojas, M., Speck, S. H., Roman, J., Brigham, K. L., & Stecenko, A. A. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00007.2005 · Cited by 106
Health-Related Quality of Life Among Patients With Idiopathic Pulmonary Fibrosis
Swigris, J. J., Gould, M. K., & Wilson, S. R. (2005) · CHEST Journal · doi:10.1378/chest.127.1.284 · Cited by 104
Korfei, M., Schmitt, S., Ruppert, C., Henneke, I., Markart, P., Loeh, B., Mahavadi, P., Wygrecka, M., Klepetko, W., Fink, L., et al. (2011) · Journal of Proteome Research · doi:10.1021/pr1009355 · Cited by 108
Aronson, K. I., Danoff, S. K., Russell, A.-M., Ryerson, C. J., Suzuki, A., Wijsenbeek, M. S., Bajwah, S., Bianchi, P., Corte, T. J., Lee, J. S., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202105-1193st · Cited by 99
Self-citationSong, J. W., Song, J., & Kim, D. S. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.11.012 · Cited by 112
MALOUF, M. A., HOPKINS, P., SNELL, G., & GLANVILLE, A. R. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.01955.x · Cited by 100
Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis
Loomis-King, H. A., Flaherty, K. R., & Moore, B. B. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.015 · Cited by 113
“Despite these promising results, a subsequent randomized-controlled trial found no benefit on duration of progression-free survival, pulmonary function or quality of life [31].”
Recent Advances in Idiopathic Pulmonary Fibrosis
Noth, I., & Martínez, F. J. (2007) · CHEST Journal · doi:10.1378/chest.06-1927 · Cited by 108
Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment
Khalil, N. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1030055 · Cited by 98
“A larger, multicentred, double-blind randomized trial evaluating the survival benefit for patients taking interferon gamma1b plus prednisone versus those taking prednisone and placebo revealed that interferon gamma-1b did not affect progression of the disease, lung function or quality of life.(77)”
BackgroundDisrupting mechanotransduction decreases fibrosis and contracture in split-thickness skin grafting
Chen, K., Henn, D., Januszyk, M., Barrera, J. A., Noishiki, C., Bonham, C. A., Griffin, M., Tevlin, R., Carlomagno, T., Shannon, T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9152 · Cited by 102
Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial
the Ifigenia study group*, Behr, J., Demedts, M., Buhl, R., Costabel, U., Dekhuijzen, R. P., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., et al. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-101 · Cited by 94
“This finding is in line with findings from previous studies and may suggest the presence of specific disease processes in severe disease states [ 15-18 ].”
ResultRazaghi, A., Owens, L., & Heimann, K. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.10.022 · Cited by 101
Kim, J. H., Kim, H. Y., Kim, S., Chung, J.-H., Park, W. S., & Chung, D. H. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61211-4 · Cited by 103
Vollmer-Conna, U. S., Piraino, B., Cameron, B., Davenport, T. A., Hickie, I. B., Wakefield, D., Lloyd, A. R., & Dubbo Infection Outcomes Study Group (2008) · Clinical Infectious Diseases · doi:10.1086/592967 · Cited by 99
“This is consistent with the observation that the administration of IFN-g to humans leads to symptoms reminiscent of the acute sickness response [ 32 ].”
ResultRegulation of Fibrosis by the Immune System
Lupher, M., & Gallatin, W. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(05)89006-6 · Cited by 101
Swigris, J. J., Esser, D., Conoscenti, C. S., & Brown, K. K. (2014) · Health and Quality of Life Outcomes · doi:10.1186/s12955-014-0124-1 · Cited by 90
“…−5.7 [-18.7, 7.2] −5.8 [-14.7, 3.1] −6.2 [-12.8, 0.3] −6.1 [-11.7, 0.5] p-value2 NS NS NS <.05 Noth et al., 2012 [26] 28 weeks 145 Warfarin – – – – Placebo – – – – p-value2 – – – NS Raghu et al., 2004 [29] 48 weeks 330 Interferon gamma 1b – – – – Placebo – – – – p-value2 – – – NS Raghu et al.,…”
InfluentialSelf-citationMesenchymal cell survival in airway and interstitial pulmonary fibrosis
Bonner, J. C. (2010) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-3-15 · Cited by 98
“This dual action may explain why IFN-g has not proven to be an effective therapy in patients with IPF [77].”
BackgroundResultInfluentialYang, T., Chen, M., & Sun, T. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350104 · Cited by 92
The St. George’s Respiratory Questionnaire as a prognostic factor in IPF
Furukawa, T., Taniguchi, H., Ando, M., Kondoh, Y., Kataoka, K., Nishiyama, O., Johkoh, T., Fukuoka, J., Sakamoto, K., & Hasegawa, Y. (2017) · Respiratory Research · doi:10.1186/s12931-017-0503-3 · Cited by 99
Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside
Ghonim, M. A., Boyd, D. F., Flerlage, T., & Thomas, P. G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170499 · Cited by 95
“IFN-γ-1b, which has preclinical data suggesting pleomorphic antifibrotic and immunoregulatory effects, was clinically tested with negative results (148).”
BackgroundDiagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines
Cottin, V., Crestani, B., Valeyre, D., Wallaert, B., Cadranel, J. L., Dalphin, J., Delaval, P., Israël‐Biet, D., Kessler, R., Reynaud‐Gaubert, M., et al. (2014) · European Respiratory Review · doi:10.1183/09059180.00001814 · Cited by 98
Șerban, A. I., Stanca, L., Geicu, O. I., Munteanu, M. C., & Dinischiotu, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152376 · Cited by 97
“Diminished levels of IFN-γ were found in patients with idiopathic pulmonary fibrosis [90] and it has been suggested that the cytokine might be used for therapeutic purposes [91].”
BackgroundS2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose
Behr, J., Günther, A., Ammenwerth, W., Bittmann, I., Bonnet, R. B., Buhl, R., Eickelberg, O., Ewert, R., Gläser, S., Gottlieb, J., et al. (2013) · Pneumologie · doi:10.1055/s-0032-1326009 · Cited by 110
“Anhand neuerer Daten aus klinischen Studien an Patienten mit erhaltener Lungenfunktion stellt sich dieses me-diane Überleben jedoch als möglicherweise zu gering dar [134 – 136].”
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Bouros, D. E., & Antoniou, K. M. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00145004 · Cited by 94
“A survival benefit (p50.04) was found in patients with mild-to-moderate disease (forced vital capacity (FVC) above the median .62% predicted) [ 23 ].”
BackgroundMethodIdiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
Spagnolo, P., Maher, T. M., & Richeldi, L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.04.005 · Cited by 94
Lin, S., Mao, R., Qian, C., Bettenworth, D., Wang, J., Li, J., Bruining, D. H., Jairath, V., Feagan, B. G., Chen, M., et al. (2021) · Physiological Reviews · doi:10.1152/physrev.00005.2021 · Cited by 91
Outcomes in idiopathic pulmonary fibrosis: A meta-analysis from placebo controlled trials
Atkins, C., Loke, Y. K., & Wilson, A. M. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.11.007 · Cited by 93
“, 2004 [20] Interferon gamma-1b 168 187 63.”
Delivery and Safety of Inhaled Interferon-γ in Idiopathic Pulmonary Fibrosis
Diaz, K. T., Skaria, S., Harris, K., Solomita, M., Lau, S., Bauer, K., Smaldone, G. C., & Condos, R. (2012) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2011.0919 · Cited by 92
Therapeutic Value of Small Molecule Inhibitor to Plasminogen Activator Inhibitor–1 for Lung Fibrosis
Huang, W.-T., Vayalil, P. K., Miyata, T., Hagood, J., & Liu, R.-M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0139oc · Cited by 86
Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
Pierson, D. M., Ionescu, D., Qing, G., Yonan, A. M., Parkinson, K., Colby, T. V., & Leslie, K. O. (2006) · Respiration · doi:10.1159/000091609 · Cited by 84
TNF-α Sensitizes Normal and Fibrotic Human Lung Fibroblasts to Fas-Induced Apoptosis
Frankel, S. K., Cosgrove, G. P., Cha, S.-I., Cool, C. D., Wynes, M. W., Edelman, B. L., Brown, K. K., & Riches, D. W. H. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0155oc · Cited by 82
“Since myofibroblasts are also present in lung tissues of patients with IPF/UIP, we next determined if TNF- and IFNwere capable of sensitizing myofibroblasts to Fas-induced apoptosis.”
BackgroundInfluentialSelf-citationKwapiszewska, G., Gungl, A., Wilhelm, J., Marsh, L. M., Thekkekara Puthenparampil, H., Sinn, K., Didiasova, M., Klepetko, W., Kosanovic, D., Schermuly, R. T., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00564-2018 · Cited by 80
Margaritopoulos, G., Vasarmidi, E., & Antoniou, K. (2016) · Core Evidence · doi:10.2147/ce.s76549 · Cited by 81
“A large randomized control trial that followed other smaller ones did not show any benefit in overall survival, and the trial was terminated early.(26,27,38) Etanercept, a TNF-α antagonist, failed to show a significant effect on FVC from baseline to 48 weeks, although the drug was generally well tolerated.”
Swigris, J. J., Kuschner, W. G., Kelsey, J. L., & Gould, M. K. (2005) · CHEST Journal · doi:10.1378/chest.127.1.275 · Cited by 86
Effects of Interferon-γ 1b on Biomarker Expression in Patients with Idiopathic Pulmonary Fibrosis
Strieter, R. M., Starko, K. M., Enelow, R. I., Noth, I., & Valentine, V. G. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200312-1670oc · Cited by 87
Self-citationHomocysteine induces endothelial dysfunction via inhibition of arginine transport.
Jin, L., Caldwell, R. B., Li-Masters, T., & Caldwell, R. W. (2007) · PubMed · Cited by 95
Pirfenidone Clinical Study Group in Japan, Taniguchi, H., Kondoh, Y., Ebina, M., Azuma, A., Ogura, T., Taguchi, Y., Suga, M., Takahashi, H., Nakata, K., et al. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-93 · Cited by 78
“The 5% change in VC may seem only a slight change, but the annual decline in VC in the placebo group is said to be approximately 150 to 200 mL in many recent clinical trials [12,21-25].”
BackgroundT cells in idiopathic pulmonary fibrosis: crucial but controversial
Deng, L., Huang, T., & Zhang, L. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01344-x · Cited by 74
“Furthermore, a striking increase in Th2 cytokines was detected in the BAL fluid of IPF patients [51, 52].”
BackgroundCytokine levels in the sera of patients with idiopathic pulmonary fibrosis
Tsoutsou, P. P., Gourgoulianis, K. I., Petinaki, E. A., Germenis, A. E., Tsoutsou, A., Mpaka, M., Efremidou, S., & Molyvdas, P.-A. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.06.016 · Cited by 78
Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study
Günther, A., Enke, B., Markart, P., Hammerl, P., Morr, H., Behr, J., Stähler, G., Seeger, W., Grimminger, F., Leconte, I., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00149205 · Cited by 78
“In the recently published interferon c-1b trial, the frequency of respiratory tract infections, severe pneumonias and death due to severe pneumonia was reported to be 56%, 8% and 1.8% respectively in the placebo group (n5168) [ 23 ].”
BackgroundInfluentialChallenges in pulmonary fibrosis {middle dot} 5: The NSIP/UIP debate
du Bois, R., & King, T. E. (2007) · Thorax · doi:10.1136/thx.2004.031039 · Cited by 77
Self-citationMesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
Tzouvelekis, A., Toonkel, R. L., Karampitsakos, Τ., Medapalli, K., Ninou, I., Aidinis, V., Bouros, D. E., & Glassberg, M. K. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00142 · Cited by 81
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease
Charbeneau, R. P., & Peters-Golden, M. L. (2005) · Clinical Science · doi:10.1042/cs20050012 · Cited by 79
Milanés-Virelles, M. T., García‐García, I., Herrera, Y. S., Valdés-Quintana, M., Valenzuela‐Silva, C., Jiménez-Madrigal, G., Ramos, T. I., Rivero, I. B., Olivera, N. F., la Osa, R. B. S.-D., et al. (2008) · BMC Infectious Diseases · doi:10.1186/1471-2334-8-17 · Cited by 76
“These actions were also evident in the results reported with IFN gamma in patients with idiopathic pulmonary fibrosis [ 34 ,35] and suggests that this cytokine could have future indications in other pulmonary diseases where fibrosis is present, although a definite effect on survival is still to be demonstrated.”
ResultThe Role of Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis
Pullamsetti, S. S., Savai, R., Dumitrascu, R., Dahal, B. K., Wilhelm, J., Königshoff, M., Zakrzewicz, D., Ghofrani, H. A., Weißmann, N., Eickelberg, O., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001725 · Cited by 82
Current and novel drug therapies for idiopathic pulmonary fibrosis
Maher, T. M., & Adamali, H. I. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s29928 · Cited by 90
“The first multicenter randomized control trial in IPF was published as recently as 2004.(5) Since then however, there has been an exponential increase in the numbers of subjects enrolling in IPF clinical trials worldwide.”
BackgroundDeterminants of initiation and progression of idiopathic pulmonary fibrosis
Kottmann, R. M., Hogan, C. M., Phipps, R. P., & Sime, P. J. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01624.x · Cited by 81
Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis
Antoniou, K. M., Pataka, A., Bouros, D. E., & Siafakas, N. M. (2006) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2006.01.002 · Cited by 76
Interstitial lung diseases in infants and children: Fig. 1—
Clément, A., & Eber, E. (2008) · European Respiratory Journal · doi:10.1183/09031936.00004707 · Cited by 78
Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis
Antoniou, K. M., Nicholson, A. G., Dimadi, M., Malagari, K., Latsi, P., Rapti, A., Tzanakis, N., Trigidou, R., Polychronopoulos, V., & Bouros, D. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00032605 · Cited by 75
“A recent retrospective analysis, performed in order to optimise selection of the end-point criteria for the study of RAGHU et al. [ 13 ], showed that mortality was the most inclusive end-point for future trials involving IFN-c 1b [27].”
BackgroundMethodInfluentialHRCT of fibrosing lung disease
Jacob, J., & Hansell, D. M. (2015) · Respirology · doi:10.1111/resp.12531 · Cited by 79
Vu, T. N., Chen, X., Foda, H. D., Smaldone, G. C., & Hasaneen, N. A. (2019) · Respiratory Research · doi:10.1186/s12931-019-1171-2 · Cited by 83
Clinical Trials: Discerning Hype From Substance
Fleming, T. R. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-6-201009210-00008 · Cited by 72
Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis
Arribillaga, L., Dotor, J., Basagoiti, M., Riezu‐Boj, J. I., Borrás‐Cuesta, F., Lasarte, J. J., Sarobe, P., Cornet, M. E., & Feijoó, E. (2010) · Cytokine · doi:10.1016/j.cyto.2010.11.019 · Cited by 72
“Moreover, clinical trials administering IFN-c have been designed for the treatment of PF [37].”
MethodComprehensive care of the patient with idiopathic pulmonary fibrosis
Lee, J. S., McLaughlin, S., & Collard, H. R. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328349721b · Cited by 80
Sakamoto, S., Muramatsu, Y., Satoh, K., Ishida, F., Kikuchi, N., Sano, G., Sugino, K., Isobe, K., Takai, Y., & Homma, S. (2015) · Respirology · doi:10.1111/resp.12477 · Cited by 70
Antioxidant status associated with inflammation in sarcoidosis: A potential role for antioxidants
Boots, A. W., Drent, M., Swennen, E. L. R., Moonen, H. J. J., Bast, A., & Haenen, G. R. M. M. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.10.007 · Cited by 71
Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis
Peikert, T., Daniels, C. E., Beebe, T. J., Meyer, K. C., & Ryu, J. H. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.03.018 · Cited by 76
Ambrosini, V., Zompatori, M., Luca, F. D., Antonia, D., Allegri, V., Nanni, C., Malvi, D., Tonveronachi, E., Fasano, L., Fabbri, M., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079962 · Cited by 75
Dyspnea in Idiopathic Pulmonary Fibrosis: A Systematic Review
Ryerson, C. J., Donesky, D., Pantilat, S. Z., & Collard, H. R. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.04.026 · Cited by 76
Lederer, D. J., Caplan‐Shaw, C., O’Shea, M. K., Wilt, J. S., Basner, R. C., Bartels, M. N., Sonett, J. R., Arcasoy, S. M., & Kawut, S. M. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01205.x · Cited by 73
“While the number of Black and Hispanic patients was relatively small, this rivals or exceeds the number in other epidemiologic studies and clinical trials in IPF (3,11), and our analyses were robust.”
ResultThe current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis
Kaarteenaho, R. L. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-43 · Cited by 82
“The percentages of the SLBs were similar in the IFIGENIA and also in the first large interferon-study [26,27].”
ResultIdiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs
Hadjicharalambous, M. R., & Lindsay, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020524 · Cited by 75
“A study of 330 IPF patients showed no effect on progression-free survival when treated with the immune-regulatory cytokine interferon-gamma-1β (IFN-γ-1β) [35].”
BackgroundUpdate on therapeutic management of idiopathic pulmonary fibrosis
Spagnolo, P., Τzouvelekis, Α., & Bonella, F. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s69716 · Cited by 78
“Following this observation, an RCT of IFN γ-1b versus placebo did not show any significant benefits in terms of progression-free survival, pulmonary function parameters, or quality of life in IPF.(28) However, subgroup analyses of patients with close treatment adherence revealed a trend towards increased survival.”
Guo, J., Fang, Y., Jiang, F., Li, L., Zhou, H., Xu, X., & Ning, W. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172712 · Cited by 73
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis
Pitre, T., Mah, J. C., Helmeczi, W., Khalid, M. F., Cui, S., Zhang, M., Husnudinov, R., Su, J. S., Banfield, L. E., Guy, B., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217976 · Cited by 72
Targeted treatments for cirrhosis
Fallowfield, J. A., & Iredale, J. P. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.423 · Cited by 68
Idiopathic Pulmonary Fibrosis: Diagnosis and Epidemiology
Olson, A. L., & Swigris, J. J. (2012) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.12.001 · Cited by 70
“Increased public and community practice awareness of IPF may also account for these trends: during the 1990s, the first large, multicenter, therapeutic trial for IPF was conceptualized and began enrolling patients.(35) Navaratnam and colleagues(26) reexamined the trends in incidence of PF in the United Kingdom through…”
BackgroundThe treatment of idiopathic pulmonary fibrosis
Woodcock, H. V., & Maher, T. M. (2014) · F1000Prime Reports · doi:10.12703/p6-16 · Cited by 74
Tomioka, H., Imanaka, K., Hashimoto, K., & Iwasaki, H. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6218 · Cited by 66
Concise Review: Tissue Engineering of Urinary Bladder; We Still Have a Long Way to Go?
Adamowicz, J., Pokrywczyńska, M., van Breda, S. V., Kloskowski, T., & Drewa, T. A. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0101 · Cited by 66
Idiopathic Pulmonary Fibrosis: Pathobiology of Novel Approaches to Treatment
Maher, T. M. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.002 · Cited by 70
Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema
Τzouvelekis, Α., Zacharis, G., Oikonomou, A., Mikroulis, D. A., Margaritopoulos, G. A., Koutsopoulos, A. V., Ántoniadis, A., Koulelidis, A., Steiropoulos, P., Boglou, P., et al. (2013) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-13-31 · Cited by 71
“presence of a causal-effect relationship between smoking and COPD and the disappointing results of the current immunosuppressive and immunomodulatory agents in patients with IPF [7-10].”
ResultRyerson, C. J., O’Connor, D., Dunne, J. V., Schooley, F., Hague, C. J., Murphy, D. T., Leipsic, J. A., & Wilcox, P. (2015) · CHEST Journal · doi:10.1378/chest.15-0003 · Cited by 71
Cottin, V., Crestani, B., Valeyre, D., Wallaert, B., Cadranel, J. L., Dalphin, J., Delaval, P., Israël‐Biet, D., Kessler, R., Reynaud‐Gaubert, M., et al. (2013) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2013.09.007 · Cited by 68
“[56] Raghu G, Brown KK, Bradford WZ, et al.”
BackgroundCottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.017 · Cited by 69
Piraino, B., Vollmer-Conna, U. S., & Lloyd, A. R. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.12.009 · Cited by 69
“Patients undergoing treatment with recombinant IFN-c report symptoms typical of the acute sickness response, although only fever, headaches and chills, but not self-reported fatigue or other symptoms have been found to be more frequent in the treated subjects than those receiving placebo in controlled trials (Gallin e…”
BackgroundIdiopathic Pulmonary Fibrosis: Natural History and Prognosis
Noble, P. W. (2006) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2005.08.003 · Cited by 65
Self-citationA progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer
Vancheri, C., & du Bois, R. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00115112 · Cited by 64
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery
Maher, T. M. (2013) · European Respiratory Review · doi:10.1183/09059180.00000913 · Cited by 63
Kaminski, N., Belperio, J. A., Bitterman, P. B., Chen, L., Chensue, S. W., Choi, A. M. K., Đačić, S., Dauber, J. H., du Bois, R. M., Enghild, J. J., et al. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0159su · Cited by 63
Self-citationNew Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis
Ding, Q., Luckhardt, T., Hecker, L., Zhou, Y., Liu, G., Antony, V. B., deAndrade, J. A., & Thannickal, V. J. (2011) · Drugs · doi:10.2165/11591490-000000000-00000 · Cited by 69
Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis
Michalski, J. E., & Schwartz, D. A. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s280958 · Cited by 67
Self-citationReview: Therapies for interstitial lung disease: past, present and future
Kim, R., & Meyer, K. C. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808096948 · Cited by 66
“Unfortunately, prior to the publication of the prospective, randomized, placebo-controlled clinical trial of interferon-g 1b for IPF [Raghu et al. 2004], reports of pharmacotherapy in the medical literature for a variety of ILDs were usually case series and retrospective and not randomized, placebo-controlled, prospec…”
BackgroundMethodInfluentialCooker, L. A., Peterson, D., Rambow, J., Riser, M. L., Riser, R. E., Najmabadi, F., Brigstock, D., & Riser, B. L. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00508.2006 · Cited by 60
“However, in a larger study IFN- treatment was not associated with clinically significant improvements in patient outcomes (42).”
Idiopathic Pulmonary Fibrosis and Gastroesophageal Reflux. Implications for Treatment
Allaix, M. E., Fisichella, P. M., Noth, I., Herbella, F. A. M., Borráez-Segura, B., & Patti, M. G. (2013) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-013-2333-z · Cited by 64
“Because pharmacological therapy is mostly ineffective, lung transplantation offers the only chance for increased survival.(3) Unfortunately, the number of available organs is limited, and in about 50 % of patients, a double lung transplant is performed.”
BackgroundTargeting Alveolar Repair in Idiopathic Pulmonary Fibrosis
Ptasinski, V., Stegmayr, J., Belvisi, M. G., Wagner, D. E., & Murray, L. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0476tr · Cited by 65
Interferon-induced sarcoidosis
Alazemi, S., & Campos, M. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2005.00651.x · Cited by 60
Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot Project
Couluris, M., Kinder, B. W., Xu, P., Gross-King, M., Krischer, J. P., & Panos, R. J. (2012) · Lung · doi:10.1007/s00408-012-9410-z · Cited by 67
Efficacy of Pirfenidone in Patients with Advanced-stage Idiopathic Pulmonary Fibrosis
Sakamoto, S., Itoh, T., Muramatsu, Y., Satoh, K., Ishida, F., Sugino, K., Isobe, K., & Homma, S. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8498 · Cited by 59
“IPF remains a progressive and fatal disease, and no treatment has been shown to be efficacious, despite several large clinical trials conducted in the past decade (8-12).”
BackgroundInterstitial lung disease in systemic sclerosis
Wells, A. U. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.08.002 · Cited by 63
Zisman, D. A., Keane, M. P., Belperio, J. A., Strieter, R. M., & Lynch, J. P. (2005) · Humana Press eBooks · doi:10.1385/1-59259-940-0:003 · Cited by 75
“This concept was challenged in a recent study of subcutaneous interferon (IFN)-γ1b (200 μg thrice weekly) in 330 patients with mild to moderate IPF (forced vital capacity [FVC] > 50% and DLCO > 30%), where a trend toward lower mortality was seen in IFN-γ1b-treated patients compared with placebo-treated patients (96).”
Jandl, K., Marsh, L. M., Mutgan, A. C., Crnković, S., Valzano, F., Zabini, D., Hoffmann, J., Foris, V., Gschwandtner, E., Klepetko, W., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202201-0142oc · Cited by 64
Metadata
- Authors
- Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E.
- Affiliations
- University of Washington (US)
- National Jewish Health (US)
- Yale University (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-08
- Volume
- 350
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108226118
- Cited by
- 652
- References
- 34
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 15 · 2021: 16 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 22 · 2016: 21 · 2015: 29 · 2014: 20 · 2013: 38 · 2012: 39
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, interferon gamma-1b, progression-free survival, corticosteroid-refractory disease, lung function, quality of life, mortality, pneumonia, constitutional symptoms, medication adherence
- MeSH terms
- Double-Blind Method, Female, Humans, Injections, Subcutaneous, Interferon-gamma, Male, Middle Aged, Pulmonary Fibrosis, Recombinant Proteins, Respiratory Function Tests, Respiratory Tract Infections, Risk, Proportional Hazards Models, Treatment Failure, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.